GOSS stock icon

Gossamer Bio

0.8789 USD
-0.0081
0.91%
At close Nov 8, 4:00 PM EST
After hours
0.8600
-0.0189
2.15%
1 day
-0.91%
5 days
1.02%
1 month
-13.83%
3 months
7.58%
6 months
16.35%
Year to date
-9.39%
1 year
47.71%
5 years
-96.18%
 

About: Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Employees: 135

0
Funds holding %
of 6,759 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

10% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 29

3% more call options, than puts

Call options by funds: $591K | Put options by funds: $576K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

10.32% less ownership

Funds ownership: 91.53% [Q1] → 81.21% (-10.32%) [Q2]

14% less funds holding

Funds holding: 109 [Q1] → 94 (-15) [Q2]

32% less capital invested

Capital invested by funds: $244M [Q1] → $166M (-$78.2M) [Q2]

58% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 26

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$4
355%
upside
Avg. target
$8
810%
upside
High target
$10
1,038%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Patrick Trucchio
45% 1-year accuracy
67 / 148 met price target
1,038%upside
$10
Buy
Reiterated
17 Sept 2024
HC Wainwright & Co.
Patrick Trucchio
45% 1-year accuracy
67 / 148 met price target
1,038%upside
$10
Buy
Reiterated
30 Aug 2024
Wedbush
Laura Chico
56% 1-year accuracy
38 / 68 met price target
355%upside
$4
Outperform
Reiterated
13 Aug 2024

Financial journalist opinion

Charts implemented using Lightweight Charts™